Novartis AG - Company Profile
Powered by 
All the sales intelligence you need on Novartis AG in one solution.
- Save hours of research time with a comprehensive
Sales Intelligence Solution.
- Understand how Novartis AG fits into your total
addressable market and Ideal Customer Profile.
- Gain competitive edge with triggers that tell you
when and how to engage with Novartis AG.
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward
Related keylists
View more- Top 10 Pharmaceutical Companies in Europe in 2022 by Market Capitalization
- Top 10 Pharma Companies in Europe in 2021 by R&D Expenditure
- Top 10 Big Biopharma Companies (Large Pharma & Large Biotech) in Europe in 2021 by Revenues
- Top 10 Pharmaceutical Companies in the World in 2022 by Market Capitalization
Novartis AG (Novartis) is a pharmaceutical company that is engaged in the research, development, manufacturing, distribution, marketing, and sale of innovative medicines. It offers a range of products in therapeutic areas such as cardiovascular, renal and metabolic, immunology, ophthalmology, respiratory, global health, neuroscience, and oncology. The company offers its products to pharmacists, private health systems, government agencies, physicians, hospitals, insurance groups, managed care providers, pharmacy benefit managers, and government-supported healthcare systems through brands such as Entresto, Cosentyx, Kesimpta, Kisqali, and Tasigna, among others, globally. It operates manufacturing facilities in the US, Switzerland, Austria, Slovenia, China, France, and Italy. Novartis is headquartered in Basel, Switzerland.
Headquarters
Switzerland
Address
Lichtstrasse 35, Basel, Basel-Stadt, 4056
Website
www.novartis.com
Telephone
41 613 241111
No of Employees
75,267
Industry
Pharmaceuticals and Healthcare
Ticker Symbol & Exchange
NOVN (SWF)
Revenue (2024)
$56.3B
8.9%
(2024 vs 2023)
EPS
XYZ
Net Income (2024)
XYZ
17.1%
(2024 vs 2023)
Market Cap*
$322.7B
Net Profit Margin (2024)
XYZ
7.5%
(2024 vs 2023)
* As of and is in US$
Novartis AG premium industry data and analytics
Products and Services
| Products | Brands |
|---|---|
| Generic Medicines and Biosimilars | Entresto |
| Pharmaceuticals: | Leqvio |
| Cancer | Vanrafia |
| XYZ | XYZ |
| XYZ | XYZ |
| XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
| Year | Event | Description |
|---|---|---|
| 2026 | Acquisitions/Mergers/Takeovers | In July, the company acquired Excellergy, Inc., a private biotech company. |
| 2026 | Acquisitions/Mergers/Takeovers | In July, the company acquired Pikavation Therapeutics, Inc. and its portfolio of PI3Kα inhibitor programs, including SNV4818 from Synnovation Therapeutics, LLC. |
| 2026 | Contracts/Agreements | In July, the company selected Cognizant for an AI-enabled integrated IT operations deal to unify and modernize applications, infrastructure, security, and workplace services. |
Competitor Comparison
| Key Parameters | Novartis AG | Johnson & Johnson | Eli Lilly and Co | Merck & Co Inc | Pfizer Inc |
|---|---|---|---|---|---|
| Headquarters | Switzerland | United States of America | United States of America | United States of America | United States of America |
| City | Basel | New Brunswick | Indianapolis | Rahway | New York City |
| State/Province | Basel-Stadt | New Jersey | Indiana | New Jersey | New York |
| No. of Employees | 75,267 | 138,200 | 50,605 | 75,000 | 75,000 |
| Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
| Name | Position | Board | Since | Age |
|---|---|---|---|---|
| Vasant Narasimhan, MD | Chief Executive Officer | Senior Management | 2018 | 50 |
| Mukul Mehta | Chief Financial Officer | Senior Management | 2026 | 53 |
| Shreeram Aradhye, MD | Chief Medical Officer; President - Global Drug Development | Senior Management | 2022 | 64 |
| Michelle Weese | Chief Corporate Affairs Officer | Senior Management | 2023 | 56 |
| Teresa Jose | Chief Audit Officer | Senior Management | 2025 | 58 |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
| Non Dignissim Eros | Proin vel | Convallis | 2026 | XY |
Still looking?
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Explorer
Access more premium companies when you subscribe to Explorer